• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    5 Things To Know In Investing This Week - The Shockwave Takeover Issue

    4/11/24 10:02:40 AM ET
    $JNJ
    $SWAV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $JNJ alert in real time by email

    The Shockwave offer that DKI predicted in December happened this week with Johnson & Johnson (NYSE:JNJ)agreeing to pay $335 per share in cash. DKI subscribers celebrated! The PMI came in  hot. Don’t want to read the details? The conclusion is “higher for longer”. More insane calls by “experts” crying for lower interest rates in order to help homebuyers ignore the fact that  it was low rates that led to this particular housing bubble and the government “help” they  want will end up in the sellers’ pockets, not the buyers’ bank accounts. The Congressional  Budget Office projects US debt to GDP will be 166% 30 years from now. I’m prepared to make  a sizeable bet with anyone reading this that we hit that mark well before 2054. DKI Advisor  and real estate expert, Howard Freedland, contributes a guest “Thing” explaining the impact  of the new settlement on realtor commissions. 

    Plus, we have one big non-Thing. We’re not covering the new employment report out Friday  because the numbers are lies. We keep getting great reports which are then revised  downwards during the following months. Plus, all the new jobs are some combination of  government creations and more part-time work. Finally, there are reports that employment has been overstated by almost a million jobs. Reporting on that is an act of political advocacy,  not financial analysis. 

    This week, we’ll address the following topics: 

    - Shockwave Medical (NASDAQ:SWAV) gets the takeover offer. Definitive agreement announced.

    - The purchasing managers index (PMI) came in hot. Regular readers can prepare for a familiar conclusion. 

    - Economically illiterate people say silly things with great confidence. We’ll help you  identify the nonsense. 

    - The CBO releases projections that would be scary if correct. The good news is the projections are lies. The bad news is the CBO is being too optimistic. 

    - Want to know the impact of the change in realtor commissions on the real estate market. DKI Board Member and real estate expert, Howard Freedland, contributes a guest  “Thing”. 

    Ready for a new week of shocking information? Let’s dive in: 

    1) Shockwave Medical Being Acquired by Johnson & Johnson: Last week, DKI reported that Shockwave Medical was in takeover talks with Johnson &  Johnson. On Friday morning, the parties announced a definitive agreement. $JNJ is buying  $SWAV for $335 in cash. Another round of applause for cardiologist and DKI Board Member,  Dr. Paul Thompson and interventional cardiologist, Dr. Dan Fram, who were instrumental in suggesting the idea and explaining the medical implications of Shockwave’s devices.

    swav_b.jpg

    More than 70% in under 4 months. That worked out well. 

    DKI Takeaway: DKI recommended Shockwave Medical $SWAV to subscribers in December at  $190. Our positive thesis was based on an expected takeover for more than $300 per share.  Boston Scientific $BSX approached Shockwave last year. They could return to bid again, but  given that the $JNJ talks have been public for more than a week and that there’s now a  breakup fee, it’s possible but unlikely they re-enter the situation. DKI subscribers made more  than 70% in under four months. This is the second DKI portfolio company to be acquired  following Houghton Mifflin which was bought for more than 4x DKI’s initial purchase price. If  that’s of interest to you, you’re welcome to subscribe. Otherwise, we’ll be happy to keep  informing you after the fact. 

    2) Purchasing Managers Index Comes in Hot: 

    The ISM Purchasing Managers Index (PMI) came in high. The index was 50.3 for March. This  was above February’s 47.8 and above expectations for 48.3. On the positive side, the  economy is expanding. On the negative side, this makes it harder for the Fed to lower rates. On the very negative side, the primary reason we have a “good” economy is due to debt-fueled governmental overspending. That’s not sustainable and is leading to debt increases  that are greater than GDP growth. 

    ism_manufacturing_pmi.jpg

    Manufacturing and prices of goods have been strengthening lately. 

    ism_services_pmi.jpg

    The Fed has struggled to get services inflation under control. Services have been relatively  weaker lately. 

    DKI Takeaway: The market was concerned that greater economic activity combined with sticky (not transitory) inflation would keep the Fed from lowering interest rates later this year.  Then Fed Chairman, Powell, calmed the market by saying he still thought the Fed would lower rates in 2024. On Thursday, Minneapolis Fed President, Neel Kashkari, came out and said he  wasn’t sure the Fed should lower at all this year. This is the chattiest group of Fed Governors  I’ve ever seen. None of them can resist an open microphone and they often contradict each  other within days. Still, the conclusion from this week’s data is “higher for longer”. 

    3) Economically Illiterate People Say Silly Things: 

    Asset gatherers are saying we need lower interest rates to avoid a recession. Congress and  the White House have been talking about lower mortgage rates and giveaways to “help”  homebuyers. Does anyone understand cause and effect? The same massive governmental  stimulus that caused inflation is keeping us out of an official recession. This doesn’t mean the  economy is good. It just means we’re pulling forward future demand in favor of consumption now. Homebuyers aren’t hurt by current mortgage rates. It was years of near-zero interest  rates that led to a housing price bubble. Subsidies for buyers will lead to higher prices, not  lower ones. 

    3-month_rates_and_yields_certificates_of_deposit.jpg

    Higher interest rates aren’t bad for everyone. Retirees and savers like this. 

    DKI Takeaway: The dominant economic narrative is that higher interest rates are crushing  the consumer with an increase in the price of mortgages and credit card debt. However, it 

    was the government keeping rates too low for too long and then debasing the dollar with  excessive debt-fueled spending that caused the inflation problem we’re seeing now in  addition to asset bubbles including higher home prices. For many Americans, higher rates,  which encourage saving and investment, have been a huge benefit. Many people are  benefitting from the opportunity to earn 4% - 5% on their cash balances instead of the .01%  we’ve seen in recent years. 

    4) CBO Says We’re Heading for 166% Debt to GDP. DKI Disagrees: 

    The Congressional Budget Office (CBO) just released projections that US debt will grow from  100% of GDP to 166% in the next 30 years. Please note that these figures completely ignore  the more than $200 trillion of off-balance sheet debt for programs like Social Security and  Medicare. Currently, our on-balance sheet debt is increasing by $1 trillion every 100 days and  the interest expense needed to service that debt is increasing on a parabolic curve (that  means it’s going up a lot and at an increasing rate). Congress has “responded” with  consistently-higher budget deficits. The only discussion about spending “cuts” really means a  slightly slower rate of spending growth. 

    cbo_debt_to_gdp.jpg

    DKI Analysis is certain these projections are pure weapons-grade bolognium. 

    DKI Takeaway: The CBO is typically hamstrung by rules that prevent them from considering  the effects of bad policy in its analysis. Still, this chart is complete nonsense. Current US on balance sheet debt is about $35 trillion on a $27 trillion economy meaning that the 100%  starting point in the chart above for 2024 isn’t right. I further believe these projections  assume a lack of recessions which cripple tax receipts, a lack of “one-time events” like the  2008 bailouts and trillions of dollars of Covid “stimmies”, and also assume future  Congressional spending restraint that is never going to happen. The US will hit debt to GDP  of 166% long before 2054, and I’m prepared to put real money up to back that opinion if  anyone wants to take the “over” on 2054. DKI has been writing about Japan’s debt problem  since 2022. The US is heading in that direction. 

    5) Real Estate Commission Chaos – What’s it Mean for You?: 

    DKI real estate advisor, Howard Freedland, weighs in on the change in realtor  commissions…The National Association of Realtors (NAR) settlement on commission  negotiation is affecting the supply of homes right now, but will have less effect on pricing  than many expect. By making the commission structure more negotiable and competitive,  and increasing buyer representation contracts, it will make the industry more responsible;  something I support. In an environment of already-tight supply, the settlement has caused  uncertainty. Most people don’t know the long-term effect on home prices from negotiated  commissions and buyer agreement. However, this is how commercial real estate has  operated for years and as a result, I don’t expect any change to pricing in the commercial property market.

    us_housing_price_index.jpeg

    Home supply has been tight leading to higher prices. 

    DKI Takeaway: The publicity of the NAR settlement is making people question whether they  should wait to sell their home, thinking there will be massive savings after the settlement is  enacted. They’re hoping for further constriction of already-tight supply. The uncertainty will  be resolved and have little long-term effect since most consumers will still need to pay for  services rendered in order for their transaction to go smoothly. The way they pay and the  people they pay may change, but any meaningful change to housing prices as a result of the  new rules is questionable at best. 

    Information contained in this report, and in each of its reports, is believed by Deep Knowledge Investing (“DKI”)  to be accurate and/or derived from sources which it believes to be reliable; however, such information is  presented without warranty of any kind, whether express or implied. DKI makes no representation as to the  completeness, timeliness, accuracy or soundness of the information and opinions contained therein or regarding  any results that may be obtained from their use. The information and opinions contained in this report and in  each of our reports and all other DKI Services shall not obligate DKI to provide updated or similar information in  the future, except to the extent it is required by law to do so. 

    The information we provide in this and in each of our reports, is publicly available. This report and each of our  reports are neither an offer nor a solicitation to buy or sell securities. All expressions of opinion in this and in each  of our reports are precisely that. Our opinions are subject to change, which DKI may not convey. DKI, affiliates of  DKI or its principal or others associated with DKI may have, taken or sold, or may in the future take or sell  positions in securities of companies about which we write, without disclosing any such transactions. 

    None of the information we provide or the opinions we express, including those in this report, or in any of our  reports, are advice of any kind, including, without limitation, advice that investment in a company’s securities is  prudent or suitable for any investor. In making any investment decision, each investor should consult with and  rely on his or its own investigation, due diligence and the recommendations of investment professionals whom  the investor has engaged for that purpose. 

    In no event shall DKI be liable, based on this or any of its reports, or on any information or opinions DKI expresses  or provides for any losses or damages of any kind or nature including, without limitation, costs, liabilities, trading  losses, expenses (including, without limitation, attorneys’ fees), direct, indirect, punitive, incidental, special or  consequential damages.

    Get the next $JNJ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    1/28/2026$262.00Equal-Weight → Overweight
    Morgan Stanley
    Johnson & Johnson
    $JNJ
    11/13/2025$230.00Sector Outperform
    Scotiabank
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    Johnson & Johnson
    $JNJ
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    Johnson & Johnson
    $JNJ
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    Johnson & Johnson
    $JNJ
    7/23/2025Hold → Buy
    Erste Group
    Johnson & Johnson
    $JNJ
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    Johnson & Johnson
    $JNJ
    12/10/2024$166.00Neutral
    BofA Securities
    More analyst ratings

    $JNJ
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Johnson & Johnson from Equal-Weight to Overweight and set a new price target of $262.00

    1/28/26 7:11:28 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on Johnson & Johnson with a new price target

    Scotiabank initiated coverage of Johnson & Johnson with a rating of Sector Outperform and set a new price target of $230.00

    11/13/25 9:14:21 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Johnson & Johnson from Neutral to Outperform and set a new price target of $203.00

    10/20/25 8:00:27 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Exec VP, CFO Wolk Joseph J

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/11/26 8:47:26 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, WWC. Innovative Medicine Taubert Jennifer L

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/11/26 8:45:44 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, CIO Swanson James D.

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    2/11/26 8:43:19 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

    The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations. LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individua

    2/11/26 5:31:00 PM ET
    $ABBV
    $AVBP
    $BDTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

    Johnson & Johnson (NYSE:JNJ) will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10th, 2026. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. View source version on businesswire.com: https://www.businesswire.com/news/home/20260209671111/en/ Media contact: [email protected] Investor contact: [email protected]

    2/9/26 4:16:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

    OMNY-AF pilot study reports 90% 12-month freedom from AFib with zero procedure-related adverse eventsi Additional data presented further reinforces the favorable and consistent safety and efficiency profile of the VARIPULSE platformii,iii,iv,v Johnson & Johnson today announced 12-month pilot-phase data from the OMNY-AF study, evaluating the investigational OMNYPULSE Platform for the treatment of symptomatic paroxysmal atrial fibrillation (AFib), during the 31st Annual AF Symposium in Boston. Initial results for 12-month outcomes across the 30-patient pilot cohort show investigators achieved 100% acute procedural success with no procedure-associated adverse events, while 56.7% of cases w

    2/6/26 7:00:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SWAV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

    For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

    8/18/21 1:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SWAV
    SEC Filings

    View All

    SEC Form S-3ASR filed by Johnson & Johnson

    S-3ASR - JOHNSON & JOHNSON (0000200406) (Filer)

    2/11/26 5:24:20 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Johnson & Johnson

    10-K - JOHNSON & JOHNSON (0000200406) (Filer)

    2/11/26 4:06:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Johnson & Johnson

    SCHEDULE 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/5/26 12:23:53 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

    SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

    2/13/24 5:13:59 PM ET
    $SWAV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

    SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

    2/13/24 5:07:58 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SWAV
    Financials

    Live finance-specific insights

    View All

    Johnson & Johnson reports Q4 and Full-Year 2025 results

    2025 Fourth-Quarter reported sales growth of 9.1% to $24.6 Billion with operational growth of 7.1%* and adjusted operational growth of 6.1%*; 2025 Fourth-Quarter earnings per share (EPS) of $2.10 and adjusted EPS of $2.46, both include $(0.10) due to the acquisition of Halda Therapeutics 2025 Full-Year reported sales growth of 6.0% to $94.2 Billion with operational growth of 5.3%* and adjusted operational growth of 4.2%*; 2025 Full-Year earnings per share (EPS) of $11.03 and adjusted EPS of $10.79, both include $(0.10) due to the acquisition of Halda Therapeutics Significant innovation including approvals of CAPLYTA for major depressive disorder and RYBREVANT FASPRO plus LAZCLUZE for

    1/21/26 6:20:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026

    Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the first quarter of 2026 of $1.30 per share on the company's common stock. The dividend is payable on March 10, 2026 to shareholders of record at the close of business on February 24, 2026. The ex-dividend date is February 24, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely p

    1/2/26 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results

    Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, January 21st to review fourth-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay

    12/15/25 4:27:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care